GoKawiilReview maps current drugs and pipeline candidates for treating MASH
A new review synthesizes the evolving treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH), the liver disease formerly called NASH, drawing on updated epidemiological data, revised diagnostic terminology, and studies on liver fibrosis assessment. It outlines existing approaches alongside emerging therapies aimed at addressing the disease's metabolic, cardiovascular and cancer-related complications.
GoKawiil's interpretation of the reporting above, not reported fact.
MASH has become a leading driver of liver disease worldwide, closely tied to obesity and diabetes, yet treatment options remain limited and diagnosis is complicated by inconsistent biopsy interpretation. Clarifying nomenclature and consolidating research on risk factors and therapies helps standardize care and accelerate development of effective drugs for a condition affecting a growing share of the global population.
- MASH is increasingly recognized as a systemic metabolic disorder with cardiovascular and cancer risks, not just a liver condition.
- Renewed diagnostic terminology (MASLD/MASH replacing NAFLD/NASH) aims to better reflect underlying metabolic causes.
- Liver biopsy variability and imaging challenges continue to complicate accurate diagnosis and monitoring of disease severity.
Source: nature.com — Gallage, 2026-09-02
Published there as: “Current therapeutic landscape and future treatment perspectives of MASH”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.